Assertio Holdings, Inc. ASRT

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
32/100
Developing

Ranked against 90 peers in Drug Manufacturers - Specialty & Generic

About Assertio Holdings, Inc.

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive … Full ASRT analysis →

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.20), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.28), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
30
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where ASRT ranks in Drug Manufacturers - Specialty & Generic

Assertio Holdings, Inc. ranks #63 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 69%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

# Company Moat score Rating
59 Canopy Growth Corporation CGC 35/100 Developing
60 SCYNEXIS, Inc. SCYX 34/100 Developing
61 Cardiol Therapeutics Inc. CRDL 33/100 Developing
62 Zhengye Biotechnology Holding L ZYBT 32/100 Developing
63 Assertio Holdings, Inc. ASRT 32/100 Developing
64 Sunshine Biopharma Inc. warrant SBFMW 31/100 Developing
65 Sunshine Biopharma Inc. SBFM 31/100 Developing
66 China Pharma Holdings, Inc. CPHI 29/100 Developing
67 Flora Growth Corp. FLGC 29/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How ASRT scores on the Corporate Default defenses

Pricing Power

Score 30 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 36 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 37 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 23 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 27 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 41 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ASRT's moat

What is Assertio Holdings, Inc.'s moat score?

Assertio Holdings, Inc. (ASRT) scores 32 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #63 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 69%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Scale & Market Position (41/100) and its weakest is Capital Efficiency (23/100).

How does Assertio Holdings, Inc. compare with other Drug Manufacturers - Specialty & Generic companies?

Assertio Holdings, Inc. ranks #63 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Zhengye Biotechnology Holding L (ZYBT) at 32 just above it and Sunshine Biopharma Inc. warrant (SBFMW) at 31 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Assertio Holdings, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Assertio Holdings, Inc.?

The Corporate Default template measures 6 defenses, and ASRT scores: Pricing Power (30), Cost Advantage (36), Customer Stickiness (37), Capital Efficiency (23), Resilience (27), Scale & Market Position (41). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000